Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48

1.

Treatment of opioid dependence with buprenorphine: current update.

Soyka M.

Dialogues Clin Neurosci. 2017 Sep;19(3):299-308.

2.

Buprenorphine/Naloxone Maintenance Therapy: an Observational Retrospective Report on the Effect of Dose on 18 months Retention in an Office-Based Treatment Program.

Parran TV, Mace AG, Dahan YJ, Adelman CA, Kolganov M.

Subst Abuse. 2017 Oct 4;11:1178221817731320. doi: 10.1177/1178221817731320. eCollection 2017.

3.

Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial.

Walsh SL, Comer SD, Lofwall MR, Vince B, Levy-Cooperman N, Kelsh D, Coe MA, Jones JD, Nuzzo PA, Tiberg F, Sheldon B, Kim S.

JAMA Psychiatry. 2017 Sep 1;74(9):894-902. doi: 10.1001/jamapsychiatry.2017.1874.

PMID:
28655025
4.

Buprenorphine requires concomitant activation of NOP and MOP receptors to reduce cocaine consumption.

Kallupi M, Shen Q, de Guglielmo G, Yasuda D, Journigan VB, Zaveri NT, Ciccocioppo R.

Addict Biol. 2018 Mar;23(2):585-595. doi: 10.1111/adb.12513. Epub 2017 Jun 21.

PMID:
28635181
5.

Long-term retention in Office Based Opioid Treatment with buprenorphine.

Weinstein ZM, Kim HW, Cheng DM, Quinn E, Hui D, Labelle CT, Drainoni ML, Bachman SS, Samet JH.

J Subst Abuse Treat. 2017 Mar;74:65-70. doi: 10.1016/j.jsat.2016.12.010. Epub 2016 Dec 30.

PMID:
28132702
6.

Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials.

Carlezon WA Jr, Krystal AD.

Depress Anxiety. 2016 Oct;33(10):895-906. doi: 10.1002/da.22500. Review.

7.

Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method.

Hämmig R, Kemter A, Strasser J, von Bardeleben U, Gugger B, Walter M, Dürsteler KM, Vogel M.

Subst Abuse Rehabil. 2016 Jul 20;7:99-105. doi: 10.2147/SAR.S109919. eCollection 2016.

8.
9.

Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study.

Ling W, Hillhouse MP, Saxon AJ, Mooney LJ, Thomas CM, Ang A, Matthews AG, Hasson A, Annon J, Sparenborg S, Liu DS, McCormack J, Church S, Swafford W, Drexler K, Schuman C, Ross S, Wiest K, Korthuis PT, Lawson W, Brigham GS, Knox PC, Dawes M, Rotrosen J.

Addiction. 2016 Aug;111(8):1416-27. doi: 10.1111/add.13375. Epub 2016 Apr 21.

10.

Extended-Release Mixed Amphetamine Salts vs Placebo for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cocaine Use Disorder: A Randomized Clinical Trial.

Levin FR, Mariani JJ, Specker S, Mooney M, Mahony A, Brooks DJ, Babb D, Bai Y, Eberly LE, Nunes EV, Grabowski J.

JAMA Psychiatry. 2015 Jun;72(6):593-602. doi: 10.1001/jamapsychiatry.2015.41.

11.

New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone.

Soyka M.

Subst Abuse Rehabil. 2015 Jan 6;6:1-14. doi: 10.2147/SAR.S45585. eCollection 2015. Review.

12.

Association between methadone dose and concomitant cocaine use in methadone maintenance treatment: a register-based study.

Baumeister M, Vogel M, Dürsteler-MacFarland KM, Gerhard U, Strasser J, Walter M, Wiesbeck GA, Petitjean SA.

Subst Abuse Treat Prev Policy. 2014 Dec 4;9:46. doi: 10.1186/1747-597X-9-46.

13.

Patient perspectives on buprenorphine/naloxone: a qualitative study of retention during the starting treatment with agonist replacement therapies (START) study.

Teruya C, Schwartz RP, Mitchell SG, Hasson AL, Thomas C, Buoncristiani SH, Hser YI, Wiest K, Cohen AJ, Glick N, Jacobs P, McLaughlin P, Ling W.

J Psychoactive Drugs. 2014 Nov-Dec;46(5):412-26. doi: 10.1080/02791072.2014.921743.

14.

Treatment of co-occurring alcohol and other drug use disorders.

Arias AJ, Kranzler HR.

Alcohol Res Health. 2008;31(2):155-67. Review.

15.

A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction.

Neumann AM, Blondell RD, Jaanimägi U, Giambrone AK, Homish GG, Lozano JR, Kowalik U, Azadfard M.

J Addict Dis. 2013;32(1):68-78. doi: 10.1080/10550887.2012.759872.

16.

A randomized investigation of methadone doses at or over 100 mg/day, combined with contingency management.

Kennedy AP, Phillips KA, Epstein DH, Reamer DA, Schmittner J, Preston KL.

Drug Alcohol Depend. 2013 Jun 1;130(1-3):77-84. doi: 10.1016/j.drugalcdep.2012.10.025. Epub 2012 Nov 26.

17.

Opioid addiction and abuse in primary care practice: a comparison of methadone and buprenorphine as treatment options.

Bonhomme J, Shim RS, Gooden R, Tyus D, Rust G.

J Natl Med Assoc. 2012 Jul-Aug;104(7-8):342-50. Review.

18.

Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: a randomized trial.

Saxon AJ, Ling W, Hillhouse M, Thomas C, Hasson A, Ang A, Doraimani G, Tasissa G, Lokhnygina Y, Leimberger J, Bruce RD, McCarthy J, Wiest K, McLaughlin P, Bilangi R, Cohen A, Woody G, Jacobs P.

Drug Alcohol Depend. 2013 Feb 1;128(1-2):71-6. doi: 10.1016/j.drugalcdep.2012.08.002. Epub 2012 Aug 22.

19.

A combination of buprenorphine and naltrexone blocks compulsive cocaine intake in rodents without producing dependence.

Wee S, Vendruscolo LF, Misra KK, Schlosburg JE, Koob GF.

Sci Transl Med. 2012 Aug 8;4(146):146ra110. doi: 10.1126/scitranslmed.3003948.

20.

Counseling and directly observed medication for primary care buprenorphine maintenance: a pilot study.

Moore BA, Barry DT, Sullivan LE, Oʼconnor PG, Cutter CJ, Schottenfeld RS, Fiellin DA.

J Addict Med. 2012 Sep;6(3):205-11. doi: 10.1097/ADM.0b013e3182596492.

Supplemental Content

Support Center